JP2019504892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504892A5 JP2019504892A5 JP2018560705A JP2018560705A JP2019504892A5 JP 2019504892 A5 JP2019504892 A5 JP 2019504892A5 JP 2018560705 A JP2018560705 A JP 2018560705A JP 2018560705 A JP2018560705 A JP 2018560705A JP 2019504892 A5 JP2019504892 A5 JP 2019504892A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nucleic acid
- acid encoding
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 210000004962 mammalian cell Anatomy 0.000 claims 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 8
- 108091008874 T cell receptors Proteins 0.000 claims 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 229940121354 immunomodulator Drugs 0.000 claims 6
- 239000002955 immunomodulating agent Substances 0.000 claims 5
- 230000002584 immunomodulator Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- -1 BLTA Proteins 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 230000004068 intracellular signaling Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100024025 Heparanase Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108010037536 heparanase Proteins 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/073489 | 2016-02-04 | ||
| CN2016073489 | 2016-02-04 | ||
| PCT/CN2016/087855 WO2017133175A1 (en) | 2016-02-04 | 2016-06-30 | Engineered mammalian cells for cancer therapy |
| CNPCT/CN2016/087855 | 2016-06-30 | ||
| PCT/CN2017/072723 WO2017133633A1 (en) | 2016-02-04 | 2017-01-26 | Engineered mammalian cells for cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504892A JP2019504892A (ja) | 2019-02-21 |
| JP2019504892A5 true JP2019504892A5 (enExample) | 2020-03-05 |
Family
ID=59499323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560705A Pending JP2019504892A (ja) | 2016-02-04 | 2017-01-26 | 癌治療のための改変哺乳類細胞 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190038671A1 (enExample) |
| EP (1) | EP3411079A4 (enExample) |
| JP (1) | JP2019504892A (enExample) |
| CN (1) | CN108883202A (enExample) |
| WO (2) | WO2017133175A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| EP3545001A4 (en) | 2016-11-22 | 2020-10-21 | Alloplex Biotherapeutics | ALLOGENIC TUMOR CELL VACCINE |
| US11185586B2 (en) | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
| AU2018223211B2 (en) * | 2017-02-21 | 2025-02-27 | The University Of Adelaide | T cells expressing chemokine receptors for treating cancer |
| SG10202111394XA (en) | 2017-04-13 | 2021-12-30 | Senti Biosciences Inc | Combinatorial cancer immunotherapy |
| EP3612222A4 (en) * | 2017-04-19 | 2020-12-23 | University of Southern California | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| GB201713078D0 (en) * | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| EP3679145A2 (en) * | 2017-09-08 | 2020-07-15 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression |
| EP3697425A1 (en) * | 2017-10-18 | 2020-08-26 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| CA3093628A1 (en) * | 2018-02-15 | 2019-08-22 | The National Institute for Biotechnology in the Negev Ltd. | Tumor environment-specific expression of chimeric antigen receptors |
| US20210113594A1 (en) * | 2018-03-13 | 2021-04-22 | Osaka University | Tumor immunomodulator |
| AU2019253562B2 (en) * | 2018-04-09 | 2025-11-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions comprising a viral vector for expression of a transgene and an effector |
| CN110615842B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含共刺激受体的嵌合抗原受体及应用 |
| CN108913718A (zh) * | 2018-07-20 | 2018-11-30 | 苏州茂行生物科技有限公司 | 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用 |
| CN108949825A (zh) * | 2018-07-30 | 2018-12-07 | 苏州茂行生物科技有限公司 | 一种靶向her2的car-t细胞的制备方法及应用 |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| JP7558151B2 (ja) * | 2018-09-05 | 2024-09-30 | アダプティミューン・リミテッド | Ｔ細胞改変 |
| CN112789293B (zh) | 2018-09-10 | 2024-05-10 | 南京传奇生物科技有限公司 | 针对cll1的单结构域抗体及其构建体 |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| AU2019359890B2 (en) | 2018-10-17 | 2024-10-24 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| KR20210112310A (ko) * | 2018-12-06 | 2021-09-14 | 광동 티씨알큐어 바이오파마 테크놀로지 씨오., 엘티디. | 종양 항원, tgf-베타 및 면역체크포인트를 표적으로 하는 tcr-t 세포 복합 치료법 |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| KR20220030205A (ko) * | 2019-02-08 | 2022-03-10 | 디앤에이 투포인토 인크. | 면역 세포의 트랜스포존 기반 변형 |
| US20220088075A1 (en) * | 2019-02-22 | 2022-03-24 | The Trustees Of The University Of Pennsylvania | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| US20220175833A1 (en) * | 2019-03-07 | 2022-06-09 | Children's Medical Center Corporation | Targeted delivery of immune-modulating vhh and vhh-fusion protein |
| WO2020219504A1 (en) * | 2019-04-23 | 2020-10-29 | The Regents Of The University Of California | Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| WO2021016598A1 (en) * | 2019-07-25 | 2021-01-28 | Immunowake Inc. | Methods of measuring cell-mediated killing by effectors |
| KR20220040476A (ko) * | 2019-08-01 | 2022-03-30 | 메모리얼 슬로안 케터링 캔서 센터 | 개선된 면역치료법을 위한 세포 및 이의 용도 |
| CN114555809A (zh) * | 2019-08-28 | 2022-05-27 | 森迪生物科学公司 | 组合癌症免疫疗法 |
| KR20220097875A (ko) | 2019-09-03 | 2022-07-08 | 마이얼로이드 테라퓨틱스, 인크. | 게놈 통합을 위한 방법 및 조성물 |
| AU2020371619A1 (en) * | 2019-10-22 | 2022-05-12 | Alloplex Biotherapeutics | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| CA3160443A1 (en) * | 2019-11-08 | 2021-05-14 | Mayo Foundation For Medical Education And Research | Methods and materials for using engineered mesenchymal stem cells to treat inflammatory conditions and degenerative diseases |
| CN112941028A (zh) * | 2019-12-09 | 2021-06-11 | 上海细胞治疗集团有限公司 | 纳米抗体基因修饰的间充质干细胞及其制备方法与应用 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| WO2021144338A1 (en) * | 2020-01-14 | 2021-07-22 | Adaptimmune Limited | Method of treatment of cancer or tumour |
| EP4110818A1 (en) * | 2020-02-26 | 2023-01-04 | Biograph 55, Inc. | C19 c38 bispecific antibodies |
| WO2021197430A1 (en) * | 2020-04-01 | 2021-10-07 | Nanjing Legend Biotech Co., Ltd. | Compositions and methods for reducing graft rejection in allogeneic cell therapy |
| CA3184225A1 (en) * | 2020-06-29 | 2022-01-06 | Steven Larson | C825 expressing immune cells and diagnostic uses thereof |
| US20230321242A1 (en) * | 2020-08-24 | 2023-10-12 | Charité - Universitätsmedizin Berlin | Chimeric antigen receptor (car)-expressing cells recognizing cea |
| AU2021368557A1 (en) * | 2020-10-27 | 2023-06-08 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using next generation engineered t cell therapy |
| MX2023005201A (es) | 2020-11-04 | 2023-06-28 | Myeloid Therapeutics Inc | Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas. |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| BR112023018832A2 (pt) | 2021-03-17 | 2023-12-26 | Myeloid Therapeutics Inc | Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas |
| EP4337268A4 (en) | 2021-05-11 | 2025-06-04 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| WO2022272102A2 (en) * | 2021-06-24 | 2022-12-29 | Georgia Tech Research Corporation | Methods and compositions for remote control of t cell therapies by thermal targeting |
| CN113789299B (zh) * | 2021-10-18 | 2023-03-24 | 新鲁细胞生物科技(海南)有限公司 | 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法 |
| JP2025533842A (ja) * | 2022-10-07 | 2025-10-09 | センティ バイオサイエンシズ インコーポレイテッド | アームドキメラ受容体およびその使用方法 |
| WO2024107410A1 (en) * | 2022-11-14 | 2024-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Cd39 selection for cytotoxicity of genetically engineered t regulatory cells |
| WO2024197157A1 (en) | 2023-03-21 | 2024-09-26 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies |
| FI20237105A1 (en) | 2023-05-29 | 2024-11-30 | Onni Biotechnologies Oy | Modified natural killer cells with enhanced cytotoxic action and greater survival |
| WO2025081190A1 (en) * | 2023-10-12 | 2025-04-17 | Georgia Tech Research Corporation | Image guided car t cell therapy to treat brain tumors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5215964A (en) * | 1991-06-03 | 1993-06-01 | Immunobiology Research Institute, Inc. | Peptides useful in regulating the immune and nervous systems |
| KR20010031762A (ko) * | 1997-11-03 | 2001-04-16 | 추후제출 | 유전자요법을 위한 과열 유도 발현 벡터 및 그의 이용 방법 |
| CN101899114A (zh) * | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| JP5709356B2 (ja) * | 2006-01-13 | 2015-04-30 | アメリカ合衆国 | 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子 |
| US20140255363A1 (en) * | 2011-09-16 | 2014-09-11 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| SG11201505896YA (en) * | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| KR20210108497A (ko) * | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| ES2857226T3 (es) * | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| NZ726989A (en) * | 2014-06-06 | 2020-08-28 | Bluebird Bio Inc | Improved t cell compositions |
| JP2017528433A (ja) * | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| HK1254803A1 (zh) * | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | 新型pd -1的免疫调节剂 |
-
2016
- 2016-06-30 WO PCT/CN2016/087855 patent/WO2017133175A1/en not_active Ceased
-
2017
- 2017-01-26 EP EP17746953.3A patent/EP3411079A4/en not_active Withdrawn
- 2017-01-26 WO PCT/CN2017/072723 patent/WO2017133633A1/en not_active Ceased
- 2017-01-26 US US16/075,220 patent/US20190038671A1/en not_active Abandoned
- 2017-01-26 CN CN201780010175.2A patent/CN108883202A/zh active Pending
- 2017-01-26 JP JP2018560705A patent/JP2019504892A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504892A5 (enExample) | ||
| Liu et al. | Turning cold tumors into hot tumors by improving T-cell infiltration | |
| Dougan et al. | Cancer immunotherapy: beyond checkpoint blockade | |
| Demaria et al. | Harnessing innate immunity in cancer therapy | |
| JP7162632B2 (ja) | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 | |
| West et al. | PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells | |
| Elias et al. | Immunotherapy comes of age: immune aging & checkpoint inhibitors | |
| Dammeijer et al. | Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors | |
| Suek et al. | Targeted APC activation in cancer immunotherapy to enhance the abscopal effect | |
| Yan et al. | Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments | |
| Elsegood et al. | Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma | |
| Draghiciu et al. | Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination | |
| JP2019500909A5 (enExample) | ||
| Zamarin et al. | Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer | |
| JP2019501670A5 (enExample) | ||
| Huang et al. | Innovative strategies to advance CAR T cell therapy for solid tumors | |
| JP2019531293A (ja) | Ｐｄ−１ペプチド阻害剤 | |
| Hu et al. | The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them | |
| Pieper et al. | Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in immunologically cold tumor models | |
| Simovic et al. | Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy | |
| Chen et al. | Enhancing the efficacy of tumor vaccines based on immune evasion mechanisms | |
| Nguyen et al. | A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma | |
| Vo et al. | Cellular immunotherapy in multiple myeloma | |
| Chekaoui et al. | Cancer vaccines: an update on recent achievements and prospects for cancer therapy | |
| IL295952A (en) | Lymphocyte population and methods for their preparation |